{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:17:55Z","timestamp":1781014675055,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK Biologicals SA","award":["HO-15-15940"],"award-info":[{"award-number":["HO-15-15940"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3759-z","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T10:03:40Z","timestamp":1549447420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0913-039X","authenticated-orcid":false,"given":"Christophe","family":"Sauboin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Holl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne A.","family":"Gershon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Benninghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Carryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wutzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"3759_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/CMR.9.3.361","volume":"9","author":"AM Arvin","year":"1996","unstructured":"Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9:361\u201381.","journal-title":"Clin Microbiol Rev"},{"key":"3759_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","volume":"368","author":"U Heininger","year":"2006","unstructured":"Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365\u201376.","journal-title":"Lancet"},{"key":"3759_CR3","unstructured":"Centers for Disease and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. Varicella. The Pink Book (12th Edition). Accessed 28 Aug 2017. Available at \n                    https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/varicella.pdf"},{"key":"3759_CR4","unstructured":"European Centre for Disease Prevention and Control: Varicella Vaccination in the European Eunion. \n                    https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/Varicella-Guidance-2015.pdf"},{"key":"3759_CR5","unstructured":"World Health Organization: Immunization, Vaccines and Biologicals: Varicella. \n                    http:\/\/www.who.int\/immunization\/diseases\/varicella\/en\n                    \n                  \/."},{"key":"3759_CR6","unstructured":"Bonmarin I, Bakao N, Seringe E et al. Epidemiologie de varicelle en France. BEH. 2005; [8]: 30\u201331."},{"key":"3759_CR7","unstructured":"World Health Organization: Systematic review of available evidence on effectivenes and duration of protection of varicella vaccines. \n                    http:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/april\/4_Systematic_review_on_effectiveness_and_duration_of_protection_of_varicella_vaccines.pdf"},{"key":"3759_CR8","first-page":"265","volume":"89","author":"WHO","year":"2014","unstructured":"WHO. Position paper: varicella and herpes zoster vaccines: WHO. Wkly Epidemiol Rec. 2014;89:265\u201387.","journal-title":"Wkly Epidemiol Rec"},{"key":"3759_CR9","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/j.1742-1241.2005.00647.x","volume":"59","author":"J Ramet","year":"2005","unstructured":"Ramet J, Weil-Olivier C, Sedlak W. Is Europe ready to embrace a policy of universal varicella vaccination? Int J Clin Pract. 2005;59:1326\u201333.","journal-title":"Int J Clin Pract"},{"key":"3759_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/01.inf.0000122606.88429.8f","volume":"23","author":"B Rentier","year":"2004","unstructured":"Rentier B, Gershon AA. Consensus: varicella vaccination of healthy children--a challenge for Europe. Pediatr Infect Dis J. 2004;23:379\u201389.","journal-title":"Pediatr Infect Dis J"},{"key":"3759_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jama.287.5.606","volume":"287","author":"JF Seward","year":"2002","unstructured":"Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606\u201311.","journal-title":"JAMA"},{"key":"3759_CR12","doi-asserted-by":"publisher","unstructured":"Siedler A, Arndt U. Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill. 2010. \n                    https:\/\/doi.org\/10.2807\/ese.15.13.19530-en.","DOI":"10.2807\/ese.15.13.19530-en."},{"key":"3759_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/14760584.2017.1343669","volume":"16","author":"P Wutzler","year":"2017","unstructured":"Wutzler P, Bonanni P, Burgess M, et al. Varicella vaccination - the global experience. Expert Rev Vaccines. 2017;16:833\u201343.","journal-title":"Expert Rev Vaccines"},{"key":"3759_CR14","doi-asserted-by":"publisher","unstructured":"Bonanni P, Breuer J, Gershon A, et al. Varicella vaccination in Europe-taking the practical approach. BMC Med. 2009. \n                    https:\/\/doi.org\/10.1186\/1741-7015-7-26\n                    \n                  .","DOI":"10.1186\/1741-7015-7-26"},{"key":"3759_CR15","doi-asserted-by":"publisher","first-page":"e1134","DOI":"10.1542\/peds.2013-0863","volume":"132","author":"SR Bialek","year":"2013","unstructured":"Bialek SR, Perella D, Zhang J, et al. Impact of a routine two-dose varicella vaccination program on varicella epidemiology. Pediatrics. 2013;132:e1134\u201340.","journal-title":"Pediatrics"},{"key":"3759_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.7326\/0003-4819-159-11-201312030-00006","volume":"159","author":"CM Hales","year":"2013","unstructured":"Hales CM, Harpaz R, Joesoef MR, et al. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med. 2013;159:739\u201345.","journal-title":"Ann Intern Med"},{"key":"3759_CR17","first-page":"9","volume":"58","author":"RE Hope-Simpson","year":"1965","unstructured":"Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9\u201320.","journal-title":"Proc R Soc Med"},{"key":"3759_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/infdis\/173.2.450","volume":"173","author":"AA Gershon","year":"1996","unstructured":"Gershon AA, LaRussa P, Steinberg S, et al. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis. 1996;173:450\u20133.","journal-title":"J Infect Dis"},{"key":"3759_CR19","first-page":"S13","volume":"109","author":"MN Oxman","year":"2009","unstructured":"Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109:S13\u20137.","journal-title":"J Am Osteopath Assoc"},{"key":"3759_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1017\/S0950268800004714","volume":"125","author":"M Brisson","year":"2000","unstructured":"Brisson M, Edmunds WJ, Gay NJ, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125:651\u201369.","journal-title":"Epidemiol Infect"},{"key":"3759_CR21","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1017\/S0950268807007893","volume":"135","author":"ML Russell","year":"2007","unstructured":"Russell ML, Schopflocher DP, Svenson L, et al. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135:908\u201313.","journal-title":"Epidemiol Infect"},{"key":"3759_CR22","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1016\/j.vaccine.2011.09.024","volume":"29","author":"P Tanuseputro","year":"2011","unstructured":"Tanuseputro P, Zagorski B, Chan KJ, et al. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine. 2011;29:8580\u20134.","journal-title":"Vaccine"},{"key":"3759_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1097\/INF.0b013e31825d33f9","volume":"31","author":"M Stein","year":"2012","unstructured":"Stein M, Cohen R, Bromberg M, et al. Herpes zoster in a partially vaccinated pediatric population in Central Israel. Pediatr Infect Dis J. 2012;31:906\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"3759_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.vaccine.2013.11.008","volume":"32","author":"R Gil Pietro","year":"2014","unstructured":"Gil Pietro R, Walter S, Gonzales Escada A, et al. Different vaccination strategies in Spain and its impact on severe varicella and zoster. Vaccine. 2014;32:277\u201383.","journal-title":"Vaccine"},{"key":"3759_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1017\/S095026880400281X","volume":"133","author":"JP Mullooly","year":"2005","unstructured":"Mullooly JP, Riedlinger K, Chun C, et al. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133:245\u201353.","journal-title":"Epidemiol Infect"},{"key":"3759_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/cid\/ciq077","volume":"52","author":"J Leung","year":"2011","unstructured":"Leung J, Harpaz R, Molinari NA, et al. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis. 2011;52:332\u201340.","journal-title":"Clin Infect Dis"},{"key":"3759_CR27","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","volume":"28","author":"R Civen","year":"2009","unstructured":"Civen R, Chaves SS, Jumaan A, et al. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J. 2009;28:954\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"3759_CR28","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1086\/430325","volume":"191","author":"AO Jumaan","year":"2005","unstructured":"Jumaan AO, Yu O, Jackson LA, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:2002\u20137.","journal-title":"J Infect Dis"},{"key":"3759_CR29","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/infdis\/jit405","volume":"208","author":"S Weinmann","year":"2013","unstructured":"Weinmann S, Chun C, Schmid DS, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. J Infect Dis. 2013;208:1859\u201368.","journal-title":"J Infect Dis"},{"key":"3759_CR30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2471\/BLT.13.132142","volume":"92","author":"AE Heywood","year":"2014","unstructured":"Heywood AE, Wang H, Macartney KK, et al. Varicella and herpes zoster hospitalizations before and after implementation of one dose varicella vaccination in Australia: an ecological study. Bull World Health Organ. 2014;92:593\u2013604.","journal-title":"Bull World Health Organ"},{"key":"3759_CR31","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.4161\/hv.34426","volume":"10","author":"A Siedler","year":"2014","unstructured":"Siedler A, Dettmann M. Hospitalization with varicella and shingles before and after introduction of childhood varicella vaccination in Germany. Hum Vaccin Immunother. 2014;10:3594\u2013600.","journal-title":"Hum Vaccin Immunother."},{"key":"3759_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/cid\/ciw296","volume":"63","author":"K Kawai","year":"2016","unstructured":"Kawai K, Yawn BP, Wollan P, et al. Increasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis. 2016;63:221\u20136.","journal-title":"Clin Infect Dis"},{"key":"3759_CR33","unstructured":"Harpaz R. The impact of the U.S. Varicella Vaccination Program on the incidence of herpes zoster. \n                    https:\/\/stacks.cdc.gov\/view\/cdc\/58913\/cdc_58913_DS1.pdf?download-document-submit=Download\n                    \n                  ."},{"key":"3759_CR34","doi-asserted-by":"publisher","first-page":"e66485","DOI":"10.1371\/journal.pone.0066485","volume":"8","author":"B Ogunjimi","year":"2013","unstructured":"Ogunjimi B, Van DP, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS One. 2013;8:e66485.","journal-title":"PLoS One"},{"key":"3759_CR35","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.vaccine.2010.02.079","volume":"28","author":"M Brisson","year":"2010","unstructured":"Brisson M, Melkonyan G, Drolet M, et al. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine. 2010;28:3385\u201397.","journal-title":"Vaccine"},{"key":"3759_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.4161\/hv.23334","volume":"9","author":"J Bilcke","year":"2013","unstructured":"Bilcke J, van Hoek AJ, Beutels P. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Hum Vaccin Immunother. 2013;9:812\u201322.","journal-title":"Hum Vaccin Immunother"},{"key":"3759_CR37","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/jmv.21173","volume":"80","author":"RJ Cohrs","year":"2008","unstructured":"Cohrs RJ, Mehta SK, Schmid DS, et al. Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol. 2008;80:1116\u201322.","journal-title":"J Med Virol"},{"key":"3759_CR38","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jmv.23749","volume":"86","author":"B Ogunjimi","year":"2014","unstructured":"Ogunjimi B, Theeten H, Hens N, et al. Serology indicates cytomegalovirus infection is associated with varicella zoster virus reactivation. J Med Virol. 2014;86:812\u20139.","journal-title":"J Med Virol"},{"key":"3759_CR39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000024920","volume":"41","author":"S Schunemann","year":"1998","unstructured":"Schunemann S, Mainka C, Wolff MH. Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology. 1998;41:98\u2013102.","journal-title":"Intervirology"},{"key":"3759_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2011.02.030","volume":"304","author":"M Birlea","year":"2011","unstructured":"Birlea M, Arendt G, Orhan E, et al. Subclinical reactivation of varicella zoster virus in all stages of HIV infection. J Neurol Sci. 2011;304:22\u20134.","journal-title":"J Neurol Sci"},{"key":"3759_CR41","first-page":"17","volume":"123","author":"A Gershon","year":"2012","unstructured":"Gershon A, Chen J, Davis L, et al. Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in vaccinated children. Trans Am Clin Climatol Assoc. 2012;123:17\u201335.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"3759_CR42","doi-asserted-by":"publisher","first-page":"e60732","DOI":"10.1371\/journal.pone.0060732","volume":"8","author":"P Poletti","year":"2013","unstructured":"Poletti P, Melegaro A, Ajelli M, et al. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PLoS One. 2013;8:e60732.","journal-title":"PLoS One"},{"key":"3759_CR43","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.clinthera.2014.12.017","volume":"37","author":"MJ Ouwens","year":"2015","unstructured":"Ouwens MJ, Littlewood KJ, Sauboin C, et al. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix. Clin Ther. 2015;37:816\u201329.","journal-title":"Clin Ther"},{"key":"3759_CR44","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1086\/522159","volume":"197","author":"MN Oxman","year":"2008","unstructured":"Oxman MN, Levin MJ. Vaccination against herpes zoster and Postherpetic neuralgia. J Infect Dis. 2008;197:S228\u201336.","journal-title":"J Infect Dis"},{"key":"3759_CR45","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(12)61461-5","volume":"383","author":"R Prymula","year":"2014","unstructured":"Prymula R, Bergsaker MR, Esposito S, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella cavvine versus one dose of monovalent vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383:1313\u201324.","journal-title":"Lancet"},{"key":"3759_CR46","doi-asserted-by":"publisher","unstructured":"Ogunjimi B, Willem L, Beutels P, et al. Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster. elife. 2015. \n                    https:\/\/doi.org\/10.7554\/elife.07116\n                    \n                  .","DOI":"10.7554\/elife.07116"},{"key":"3759_CR47","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","volume":"48","author":"AA Gershon","year":"2010","unstructured":"Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48:S2\u20137.","journal-title":"J Clin Virol"},{"key":"3759_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.epidem.2016.11.001","volume":"19","author":"I Marinelli","year":"2017","unstructured":"Marinelli I, van Lier A, de Melker H, et al. Estimation of age-specific rates of reactivation and immune boosting of the varicella zoster virus. Epidemics. 2017;19:1\u201312.","journal-title":"Epidemics"},{"key":"3759_CR49","first-page":"729","volume":"63","author":"CM Hales","year":"2014","unstructured":"Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729\u201331.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"3759_CR50","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u201396.","journal-title":"N Engl J Med"},{"key":"3759_CR51","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","volume":"29","author":"AJ Hoek van","year":"2011","unstructured":"van Hoek AJ, Melegaro A, Zagheni E, et al. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine. 2011;29:2411\u201320.","journal-title":"Vaccine"},{"key":"3759_CR52","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92:1806\u201321.","journal-title":"Mayo Clin Proc"},{"key":"3759_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151319","volume":"11","author":"IA Korostil","year":"2016","unstructured":"Korostil IA, Regan DG. Varicella-zoster virus in Perth, Western Australia: seasonality and reactivation. PLoS One. 2016;11:e0151319.","journal-title":"PLoS One"},{"key":"3759_CR54","unstructured":"Institut National de la Statistique et des etudes Economiques: Estimation de la population au 1 er janvier 2016, Series par region, departement, sexe et \u03b2ge de 1975 a 2016. INSEE. Available at \n                    https:\/\/www.insee.fr\/fr\/statistiques\/1893198"},{"key":"3759_CR55","unstructured":"Silverman B, Hemo B, Friedman N. Varicella vaccine effectiveness in a israeli health maintenance organisation. Abstract presented at: 27th Annual Meeting of the European Society for Pediatric Infectious Diseases; Brussels, Belgium. 2009."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3759-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3759-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3759-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T19:10:42Z","timestamp":1580929842000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3759-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3759"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3759-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable for modelling studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CS, BB, and SC are employed by the GSK group of companies and hold shares in the GSK group of companies as part of their employee remuneration. KH was employed by the GSK group of companies and holds shares as part of her employee remuneration. PW and MB have nothing to disclose. PB reports a grant from the Center for Diseases Control (CCM) in Italy for a project dealing with the disease burden of herpes zoster. AAG reports grants from NIH, personal fees from Merck and the GSK group of companies, and lab support from Merck, outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"126"}}